Table 1.
Patient demographics and baseline disease characteristics
| Demographic or characteristic | CORAL (n = 257) | LY.12 (n = 221) | Total (N = 478) |
|---|---|---|---|
| Mean age (range), y | 51 (19-66) | 54 (25-71) | 53 (19-71) |
| Sex | |||
| Female | 91 (35) | 84 (38) | 175 (37) |
| Male | 166 (65) | 137 (62) | 303 (63) |
| IPI score * | |||
| 0 to 1 | 125 (50) | 98 (44) | 223 (47) |
| 2 | 73 (29) | 72 (33) | 145 (31) |
| ≥3 | 52 (21) | 51 (23) | 103 (22) |
| Disease stage | |||
| I | 43 (17) | 21 (10) | 64 (13) |
| II | 64 (25) | 64 (29) | 128 (27) |
| III | 43 (17) | 55 (25) | 98 (21) |
| IV | 105 (41) | 81 (36) | 186 (39) |
| LDH > upper limit of normal | 111 (44) | 99 (45) | 210 (44) |
| Rituximab included in initial and salvage therapy | 135 (53) | 123 (56) | 258 (54) |
| Stage ≥3 | 150 (58) | 136 (62) | 285 (60) |
| Prior radiotherapy | 74 (29) | 54 (24) | 128 (27) |
| B symptoms | 48 (19) | 58 (27) | 106 (23) |
| Response to first line therapy | |||
| CR, CRu, PR | 233 (91) | 184 (83) | 417 (87) |
| PD, SD | 24 (9) | 37 (17) | 61 (13) |
Values are n (%) unless otherwise indicated.
CR, complete remission; Cru, complete remission unconfirmed; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial remission; SD, stable disease.
*
IPI was determined at time of salvage chemotherapy.